Metastatic Colorectal Cancer Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: April 13, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 15.63 billion |
|
Market Size Value in 2031 |
US$ 22.41 billion |
|
CAGR |
4.09% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Treatment Regime, Therapy, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global metastatic colorectal cancer therapeutics market was valued at US$ 15.63 billion in 2022 and is expected to register a revenue CAGR of 4.09% to reach US$ 22.41 billion by 2031.
Metastatic Colorectal Cancer Therapeutics Market Fundamentals
Colorectal cancer (CRC) is the third most prevalent malignancy, with metastasis being the leading cause of death in most cases. The liver and the peritoneum are common sites of distant metastases. CRC begins in the colon or rectum. Depending on where they begin, these malignancies are sometimes known as colon cancer or rectal cancer. Colon and rectal cancers are sometimes lumped together since they have many characteristics. Polyps, mushroom-like growths inside the colon, can become malignant, or cells along the lining of the colon or rectum can mutate and grow out of control, becoming a tumor. Metastatic colorectal cancer is CRC that has progressed to the lungs, liver, or other organs.
[67867]
Metastatic Colorectal Cancer Therapeutics Market Dynamics
The real cause of colorectal cancer still remains unknown. However, several environmental and genetic variables raise the likelihood of acquiring the condition. The prevalence of CRC has decreased in recent years due to increased screening and diagnosis and improved therapies. The global metastatic colorectal cancer therapeutics market revenue is expected to grow steadily during the forecast period from 2023 to 2031. Factors such as introducing new front-line medicines, growing pipeline drugs, and favorable government efforts are expected to drive market revenue growth. Government attempts to make treatments more accessible and cheaper, and favorable reimbursement regulations are projected to drive market revenue growth.
However, some restraining factors can hamper the revenue growth of metastatic colorectal cancer. Many new medicines that target mCRC are expensive, making them out of reach for some patients. Another impediment is the emergence of drug resistance. Some individuals may develop resistance to particular medicines over time, limiting therapy efficacy.
Metastatic Colorectal Cancer Therapeutics Market Ecosystem
The global metastatic colorectal cancer therapeutics market is analyzed from four perspectives: treatment regime, therapy, end user, and region.
Metastatic Colorectal Cancer Therapeutics Market by Treatment Regime
[767886]
Based on the treatment regime, the global metastatic colorectal cancer therapeutics market is segmented into monotherapy and combination therapy.
The monotherapy segment dominates the global colorectal cancer market due to its effectiveness in treating colorectal cancer in its early stages. Monotherapy refers to the use of a single drug to treat a particular disease, and in the case of colorectal cancer, it involves the use of chemotherapy drugs. Chemotherapy drugs can kill cancer cells by interfering with their ability to divide and multiply. Monotherapy drugs used to treat colorectal cancer, such as 5-fluorouracil (5-FU), irinotecan, and oxaliplatin, are highly effective in shrinking tumors and improving patient outcomes. Furthermore, monotherapy drugs can be administered orally or intravenously, making them easier to use and more convenient for patients.
The combination therapy segment accounts for the fastest-growing revenue share in the global market. Combination therapy involves using two or more treatments, such as chemotherapy and targeted therapy, which work together to attack the cancer cells from multiple angles. This approach can improve treatment outcomes and increase the chances of a successful outcome for patients with colorectal cancer. Combination therapy can reduce the side effects of individual treatments by using lower doses of each treatment. This can improve patient tolerance and reduce the risk of treatment-related complications, improving patient quality of life. Targeted therapies are drugs designed to target specific molecules or pathways involved in the growth and spread of cancer cells. The results of these trials drive the development of new treatment regimens that are more effective and better tolerated by patients. Patients are increasingly interested in personalized treatment options that take into account their individual medical history, genetic makeup, and other factors. Combination therapy can be customized to meet individual patient's needs, improving patient satisfaction and treatment adherence.
Metastatic Colorectal Cancer Therapeutics Market by Therapy
Based on the therapy, the global metastatic colorectal cancer therapeutics market is segmented into chemotherapy, targeted therapy, immunotherapy, and others.
Chemotherapy is a standard treatment for colorectal cancer and is one of the most commonly used treatment options. Therefore, the chemotherapy segment dominates the global colorectal cancer market with the largest revenue share. Chemotherapy drugs work by killing rapidly dividing cancer cells in the body. Most commonly used as the chemotherapy for treating colorectal cancer 5-Fluorouracil (5-FU), Capecitabine (Xeloda) (a pill that is changed into 5-FU once it gets to the tumor), Irinotecan (Camptosar), Oxaliplatin (Eloxatin), Trifluridine and tipiracil (Lonsurf) (a combination drug in pill form). Chemotherapy can also be used to treat advanced or metastatic colorectal cancer. Chemotherapy is a well-established treatment option for colorectal cancer and has been extensively studied. As a result, regulatory agencies such as the FDA have approved several chemotherapy drugs to treat colorectal cancer. These drugs have a proven track record of safety and efficacy, which makes them a reliable treatment option for doctors and patients. Moreover, the chemotherapy segment dominates the global colorectal cancer market revenue because of its effectiveness in improving patient outcomes.
The targeted therapy and immune therapy segment accounts for the prominent revenue share in the global market. Targeted therapies and immunotherapies target specific molecules or pathways involved in the growth and spread of cancer cells while leaving healthy cells intact. This specificity and precision can improve treatment outcomes and reduce the risk of side effects compared to traditional chemotherapy. The development of targeted therapies for colorectal cancer has increased in recent years, providing new treatment options for patients. These therapies are designed to work with other treatments, such as chemotherapy, to improve treatment outcomes. Immunotherapy involves using the body's immune system to fight cancer cells. Recent advances in this field, such as immune checkpoint inhibitors, have shown promise in treating colorectal cancer by boosting the immune system's ability to recognize and attack cancer cells. Targeted therapies and immunotherapies can be customized to the patient's medical history, genetic makeup, and other factors.
Metastatic Colorectal Cancer Therapeutics Market by End User
Based on the end user, the global metastatic colorectal cancer therapeutics market is segmented into hospitals, cancer centers, ambulatory surgical centers, and others.
The hospital segment registered the largest revenue share in the global metastatic colorectal cancer therapeutics market in 2022. Hospitals are equipped with specialized facilities such as surgical suites, radiation therapy units, and oncology departments that are necessary for cancer diagnosis, treatment, and management. These facilities enable hospitals to offer comprehensive care to patients with colorectal cancer. Hospitals have a team of highly skilled healthcare professionals trained in diagnosis and treatment, including oncologists, surgeons, radiation therapists, and nurses. These professionals work together to provide coordinated and personalized patient care, which can improve patient outcomes. Hospitals can access the latest medical technology, including imaging and diagnostic equipment, surgical tools, and radiation therapy machines. This technology enables hospitals to provide precise and targeted treatment to colorectal cancer patients, improving treatment outcomes and reducing side effects. Hospitals have a vast referral network of healthcare providers, including primary care physicians, gastroenterologists, and other specialists, who refer patients to hospitals for treatment. This network increases the patient pool for hospitals and enables them to offer comprehensive care to patients with colorectal cancer. Most insurance plans cover treatment in a hospital setting, which makes hospitals the preferred choice for patients with colorectal cancer.
Metastatic Colorectal Cancer Therapeutics Market by Region
Based on the region, the global metastatic colorectal cancer therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America has one of the highest cases of colorectal cancer in the world. According to the American Cancer Society, colorectal cancer is the third most common cancer diagnosed in men and women in the U.S. The large prevalence of the disease creates a large patient population that drives the growth of the colorectal cancer market in the region. North America has some of the most advanced healthcare facilities in the world, including hospitals, cancer centers, and research institutions. These facilities are equipped with state-of-the-art technology and staffed by highly skilled healthcare professionals, which enables them to offer comprehensive and advanced care to patients with colorectal cancer. Insurance plans, including public programs such as Medicare and Medicaid, largely fund healthcare in North America. These programs provide coverage for colorectal cancer screening, diagnosis, and treatment, which makes it easier for patients to access care and for healthcare providers. North America has a robust research and development infrastructure that supports the development of new and innovative therapies for colorectal cancer. This infrastructure includes academic institutions, pharmaceutical companies, and biotech startups, which work together to advance the understanding of the disease and develop new treatments. North America has seen increasing adoption of colorectal cancer screening programs in recent years, enabling early detection and treatment of the disease. Early detection of colorectal cancer can significantly improve patient outcomes, contributing to the revenue growth of the colorectal cancer market in the region.
Metastatic Colorectal Cancer Therapeutics Market Competitive Landscape
The prominent players operating in the global metastatic colorectal cancer therapeutics market are:
A metastasis occurs when a recurrence occurs in an area other than the colon or rectum. In other circumstances, when colorectal cancer is identified, it has migrated to distant areas known as metastatic colorectal cancer (stage IV).
The global metastatic colorectal cancer therapeutics market was valued at US$ 15.63 billion in 2022.
The chemotherapy segment dominates the global metastatic colorectal cancer therapeutics market with the largest revenue share.
The high cost of the treatment and impediment is the emergence of drug resistance are some of the key restraints in the global metastatic colorectal cancer therapeutics market revenue growth.
The major players operating in the global metastatic colorectal cancer therapeutics market are Amgen Inc., Pfizer Inc., Sanofi S.A., and Novartis AG.
*Insights on financial performance are subject to the availability of information in the public domain